होम
एक्सप्लोर
nav.journalClub
ट्रेंडिंग
और
synapse
⌘+K
भाषा
हिन्दी
हिन्दी
April 10, 2026
Open Access
Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis
KL
Kristina Lend
Karolinska Institutet
JT
Jos W. R. Twisk
Amsterdam University Medical Centers
FK
Frieda A. Koopman
Amsterdam University Medical Centers
See all
Key Points
This research aims to assess the risk of flares in early rheumatoid arthritis patients using different bridging therapies.
Clinical trial with specific identifiers (EudraCT 2011-004720-35, ClinicalTrials.gov NCT01491815)
Comparison of oral glucocorticoids with methotrexate versus intra-articular triple therapy
Evaluation of flare incidents in participants during treatment.
Identification of flare risk levels associated with each bridging method
Comparison outcomes highlighting differences in flare rates
Potential recommendations for improved management strategies.
Abstract
EudraCT 2011-004720-35; ClinicalTrials.gov NCT01491815.
Read Full Paper
externally
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis | Synapse
Cite This Study
Copy
Lend et al. (Mon,) studied this question.
synapsesocial.com/papers/69d893c96c1944d70ce04bee
https://doi.org/https://doi.org/10.1111/joim.70094